SANDOZ DULOXETINE CAPSULE (DELAYED RELEASE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

DULOXETINE (DULOXETINE HYDROCHLORIDE)

Prieinama:

SANDOZ CANADA INCORPORATED

ATC kodas:

N06AX21

INN (Tarptautinis Pavadinimas):

DULOXETINE

Dozė:

30MG

Vaisto forma:

CAPSULE (DELAYED RELEASE)

Sudėtis:

DULOXETINE (DULOXETINE HYDROCHLORIDE) 30MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/100

Recepto tipas:

Prescription

Gydymo sritis:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0152350001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2016-05-02

Prekės savybės

______________________________________________________________________________
_Sandoz Duloxetine Product Monograph_
_ Page 1 of 84_
PRODUCT MONOGRAPH
PR SANDOZ DULOXETINE
Duloxetine Delayed-Release Capsules
30 mg and 60 mg duloxetine (as duloxetine hydrochloride)
Manufacturer’s standard
ANALGESIC/ANTIDEPRESSANT/ANXIOLYTIC
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville,
Quebec
J4B 1E6
Submission
Control No: 259736 DATE OF REVISION: June 3, 2022
______________________________________________________________________________
_Sandoz Duloxetine Product Monograph_
_ Page 2 of 84_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT
INFORMATION......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
5
WARNINGS AND PRECAUTIONS
...............................................................................
6
ADVERSE REACTIONS
................................................................................................
19
DRUG INTERACTIONS
................................................................................................
39
DOSAGE AND ADMINISTRATION
............................................................................
42
OVERDOSAGE
..............................................................................................................
45
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 46
STORAGE AND STABILITY
........................................................................................
49
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................ 49
PART II: SCIENTIFIC INFORMATION
..............................................................................
51
PHARMACEUTICAL INFORMATION
..........